Differential Expression of Thymus and Activation Regulated Chemokine and Its Receptor CCR4 in Nodal and Cutaneous Anaplastic Large-Cell Lymphomas and Hodgkin's Disease

Recent studies demonstrated that Hodgkin/Reed-Sternberg (H/RS) cells in Hodgkin’s disease (HD) express thymus and activation-regulated chemokine (TARC), whereas reactive lymphocytes surrounding H/RS cells express its ligand, CC-chemokine receptor 4 (CCR4). Because in vitro studies showed that CCR4 e...

Full description

Saved in:
Bibliographic Details
Published in:Modern pathology 2002-08, Vol.15 (8), p.838-844
Main Authors: Vermeer, M. H, Dukers, D. F, ten Berge, R. L, Bloemena, E, Wu, L, Vos, W, de Vries, E, Tensen, C. P, Meijer, C. J. L. M, Willemze, R
Format: Article
Language:English
Subjects:
ALCL
Alkaline Phosphatase - metabolism
CCR4
Chemokine
Chemokine CCL17
Chemokines, CC - biosynthesis
Hodgkin Disease - metabolism
Humans
Immunohistochemistry
Laboratory Medicine
Lymphoma, Large-Cell, Anaplastic - metabolism
Lymphomatoid Papulosis - metabolism
Medicine
Medicine & Public Health
original-article
Pathology
Receptors, CCR4
Receptors, Chemokine - biosynthesis
Skin Neoplasms - metabolism
TARC
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent studies demonstrated that Hodgkin/Reed-Sternberg (H/RS) cells in Hodgkin’s disease (HD) express thymus and activation-regulated chemokine (TARC), whereas reactive lymphocytes surrounding H/RS cells express its ligand, CC-chemokine receptor 4 (CCR4). Because in vitro studies showed that CCR4 expression is a marker for lymphocytes bearing a T-helper 2 (Th2) phenotype, it was suggested that expression of TARC is a new immune escape mechanism in HD. To find out whether this mechanism might also be operative in CD30+ malignant lymphomas other than HD, TARC and CCR4 expression was investigated by immunohistochemistry on paraffin and frozen-tissue sections of 39 nodal CD30+ anaplastic large cell lymphomas (ALCL), including 27 ALK-negative and 12 ALK-positive ALCL, 25 primary cutaneous CD30+ ALCL, including 11 patients with lymphomatoid papulosis, and 31 cases of HD. TARC was expressed by the neoplastic cells in 12/27 (44%) nodal ALK-negative ALCL and all cases of classic HD, but not in nodal ALK-positive ALCL (0/12) and only rarely in primary cutaneous CD30+ ALCL (3/25). In contrast, CCR4 was expressed by the neoplastic cells in 9/9 cutaneous CD30+ ALCL, and in 9/15 (60%) nodal ALK-negative ALCL, but only in 1/4 (25%) nodal ALK-positive ALCL and not by the H/RS cells in HD (0/8). Apart from three cases of HD showing 10 to 15% CCR4-positive lymphocytes surrounding TARC-positive H/RS cells, CCR4-positive reactive T cells were few (
ISSN:0893-3952
1530-0285
DOI:10.1097/01.MP.0000021006.53593.B0